U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06800261) titled 'Clinical Trial of PCV24 in Infants Aged 2-23 Months' on Jan. 23.
Brief Summary: A Phase 1b clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 42 days)-23 months.
The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase Ib clinical trial.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Pneumococcal Infectious Disease
Intervention:
BIOLOGICAL: Sinovac PCV24
Sinovac PCV24 (0.5 mL) is admin...